Instead, we found some reports that supported our findings of the prognosis, such as reports of poor prognosis for the TP53 mutation group in breast cancer21,71 and bladder cancer72, and no prognostic impact of TP53 status in colon cancer and rectal cancer24,73. This evidence concerns the gene TP53 and malignant colon neoplasm.